XRCC4 and ovarian cancer: More importantly, we also found that pharmaceutical inhibition of JNK significantly led to the downregulation of XRCC4 in the tumor cells and suppressed the tumor growth in the in vivo model (Figure 7e), indicating the important role of JNK-cJUN-XRCC4 in the response of cisplatin-resistant ovarian cancer cells to cisplatin treatment.